Medical Care

Global Central Nervous System Biomarker Detection Market Research Report 2025

The global market for Central Nervous System Biomarker Detection was valued at US$ 8800 million in the year 2024 and is projected to reach a revised size of US$ 16460 million by 2031, growing at a CAGR of 9.4% during the forecast period.
Central nervous system biomarker detection refers to the identification of specific biomolecules or physiological indicators related to central nervous system diseases through measurement of body fluids (such as blood, cerebrospinal fluid) or imaging methods, for early diagnosis, disease monitoring, efficacy evaluation, and prognosis prediction of diseases. These biomarkers typically include proteins, genetic and epigenetic markers, metabolites, and imaging markers. The core value of the detection lies in improving the diagnostic accuracy of neurological diseases such as Alzheimer's disease, Parkinson's disease, multiple sclerosis, etc., and promoting the development of personalized medicine.
In recent years, the global market size for central nervous system biomarker detection has been continuously growing. The increasing burden of diseases, technological advancements, and the development of personalized medicine are the main driving factors. With the intensification of global aging, the number of patients with neurodegenerative diseases such as Alzheimer's disease and Parkinson's disease has surged; The breakthroughs in gene sequencing and imaging technology have driven the discovery of biomarkers, and artificial intelligence and machine learning provide more accurate and efficient data analysis for biomarker detection; In addition, biomarkers play an important role in developing personalized healthcare plans, and all of these factors have promoted market expansion. In the global market, well-known companies such as Roche, Merck, Takeda, etc. have occupied a large market share with advanced research facilities, technology, and a large amount of resource investment, and have accumulated rich experience in research and clinical applications. Overall, local enterprises such as Dian Diagnostics are still in the catching up stage, and their competitiveness is gradually improving with the continuous breakthroughs in technology and the gradual expansion of the market. The challenges in the market mainly lie in technological bottlenecks, data privacy and ethical controversies over early diagnosis. The development trend of the future market is technological innovation, improvement of detection accuracy and efficiency, personalized and precise diagnosis and treatment, and further expansion of application fields.
This report aims to provide a comprehensive presentation of the global market for Central Nervous System Biomarker Detection, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Central Nervous System Biomarker Detection.
The Central Nervous System Biomarker Detection market size, estimations, and forecasts are provided in terms of and revenue ($ millions), considering 2024 as the base year, with history and forecast data for the period from 2020 to 2031. This report segments the global Central Nervous System Biomarker Detection market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Central Nervous System Biomarker Detection companies, new entrants, and industry chain related companies in this market with information on the revenues for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.
Market Segmentation
By Company
Roche
Merck
Takeda
Pfizer
GSK
Novartis
BristolMyers Squibb
Biogen
Celgene
AbbVie
Johnson And Johnson
Amgen
Eli Lilly
Sanofi
AstraZeneca
Quanterix
Biology Leader
Dian Diagnostics
Roadak
Delta Med Biotech
Segment by Type
Genetic Biomarkers Detection
Protein Biomarkers Detection
Metabolic Biomarkers Detection
Neuroimaging Biomarkers Detection
Segment by Application
Disease Diagnosis And Classification
Surveillance
Prognosis
Drug Development
Others
By Region
North America
United States
Canada
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Europe
Germany
France
U.K.
Italy
Russia
Nordic Countries
Rest of Europe
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by Type, by Application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of Central Nervous System Biomarker Detection company competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6, 7, 8, 9, 10: North America, Europe, Asia Pacific, Latin America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 11: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 12: The main points and conclusions of the report.
1 Report Overview
1.1 Study Scope
1.2 Market Analysis by Type
1.2.1 Global Central Nervous System Biomarker Detection Market Size Growth Rate by Type: 2020 VS 2024 VS 2031
1.2.2 Genetic Biomarkers Detection
1.2.3 Protein Biomarkers Detection
1.2.4 Metabolic Biomarkers Detection
1.2.5 Neuroimaging Biomarkers Detection
1.3 Market by Application
1.3.1 Global Central Nervous System Biomarker Detection Market Growth by Application: 2020 VS 2024 VS 2031
1.3.2 Disease Diagnosis And Classification
1.3.3 Surveillance
1.3.4 Prognosis
1.3.5 Drug Development
1.3.6 Others
1.4 Assumptions and Limitations
1.5 Study Objectives
1.6 Years Considered
2 Global Growth Trends
2.1 Global Central Nervous System Biomarker Detection Market Perspective (2020-2031)
2.2 Global Central Nervous System Biomarker Detection Growth Trends by Region
2.2.1 Global Central Nervous System Biomarker Detection Market Size by Region: 2020 VS 2024 VS 2031
2.2.2 Central Nervous System Biomarker Detection Historic Market Size by Region (2020-2025)
2.2.3 Central Nervous System Biomarker Detection Forecasted Market Size by Region (2026-2031)
2.3 Central Nervous System Biomarker Detection Market Dynamics
2.3.1 Central Nervous System Biomarker Detection Industry Trends
2.3.2 Central Nervous System Biomarker Detection Market Drivers
2.3.3 Central Nervous System Biomarker Detection Market Challenges
2.3.4 Central Nervous System Biomarker Detection Market Restraints
3 Competition Landscape by Key Players
3.1 Global Top Central Nervous System Biomarker Detection Players by Revenue
3.1.1 Global Top Central Nervous System Biomarker Detection Players by Revenue (2020-2025)
3.1.2 Global Central Nervous System Biomarker Detection Revenue Market Share by Players (2020-2025)
3.2 Global Top Central Nervous System Biomarker Detection Players by Company Type and Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.3 Global Key Players Ranking by Central Nervous System Biomarker Detection Revenue
3.4 Global Central Nervous System Biomarker Detection Market Concentration Ratio
3.4.1 Global Central Nervous System Biomarker Detection Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Central Nervous System Biomarker Detection Revenue in 2024
3.5 Global Key Players of Central Nervous System Biomarker Detection Head office and Area Served
3.6 Global Key Players of Central Nervous System Biomarker Detection, Product and Application
3.7 Global Key Players of Central Nervous System Biomarker Detection, Date of Enter into This Industry
3.8 Mergers & Acquisitions, Expansion Plans
4 Central Nervous System Biomarker Detection Breakdown Data by Type
4.1 Global Central Nervous System Biomarker Detection Historic Market Size by Type (2020-2025)
4.2 Global Central Nervous System Biomarker Detection Forecasted Market Size by Type (2026-2031)
5 Central Nervous System Biomarker Detection Breakdown Data by Application
5.1 Global Central Nervous System Biomarker Detection Historic Market Size by Application (2020-2025)
5.2 Global Central Nervous System Biomarker Detection Forecasted Market Size by Application (2026-2031)
6 North America
6.1 North America Central Nervous System Biomarker Detection Market Size (2020-2031)
6.2 North America Central Nervous System Biomarker Detection Market Growth Rate by Country: 2020 VS 2024 VS 2031
6.3 North America Central Nervous System Biomarker Detection Market Size by Country (2020-2025)
6.4 North America Central Nervous System Biomarker Detection Market Size by Country (2026-2031)
6.5 United States
6.6 Canada
7 Europe
7.1 Europe Central Nervous System Biomarker Detection Market Size (2020-2031)
7.2 Europe Central Nervous System Biomarker Detection Market Growth Rate by Country: 2020 VS 2024 VS 2031
7.3 Europe Central Nervous System Biomarker Detection Market Size by Country (2020-2025)
7.4 Europe Central Nervous System Biomarker Detection Market Size by Country (2026-2031)
7.5 Germany
7.6 France
7.7 U.K.
7.8 Italy
7.9 Russia
7.10 Nordic Countries
8 Asia-Pacific
8.1 Asia-Pacific Central Nervous System Biomarker Detection Market Size (2020-2031)
8.2 Asia-Pacific Central Nervous System Biomarker Detection Market Growth Rate by Region: 2020 VS 2024 VS 2031
8.3 Asia-Pacific Central Nervous System Biomarker Detection Market Size by Region (2020-2025)
8.4 Asia-Pacific Central Nervous System Biomarker Detection Market Size by Region (2026-2031)
8.5 China
8.6 Japan
8.7 South Korea
8.8 Southeast Asia
8.9 India
8.10 Australia
9 Latin America
9.1 Latin America Central Nervous System Biomarker Detection Market Size (2020-2031)
9.2 Latin America Central Nervous System Biomarker Detection Market Growth Rate by Country: 2020 VS 2024 VS 2031
9.3 Latin America Central Nervous System Biomarker Detection Market Size by Country (2020-2025)
9.4 Latin America Central Nervous System Biomarker Detection Market Size by Country (2026-2031)
9.5 Mexico
9.6 Brazil
10 Middle East & Africa
10.1 Middle East & Africa Central Nervous System Biomarker Detection Market Size (2020-2031)
10.2 Middle East & Africa Central Nervous System Biomarker Detection Market Growth Rate by Country: 2020 VS 2024 VS 2031
10.3 Middle East & Africa Central Nervous System Biomarker Detection Market Size by Country (2020-2025)
10.4 Middle East & Africa Central Nervous System Biomarker Detection Market Size by Country (2026-2031)
10.5 Turkey
10.6 Saudi Arabia
10.7 UAE
11 Key Players Profiles
11.1 Roche
11.1.1 Roche Company Details
11.1.2 Roche Business Overview
11.1.3 Roche Central Nervous System Biomarker Detection Introduction
11.1.4 Roche Revenue in Central Nervous System Biomarker Detection Business (2020-2025)
11.1.5 Roche Recent Development
11.2 Merck
11.2.1 Merck Company Details
11.2.2 Merck Business Overview
11.2.3 Merck Central Nervous System Biomarker Detection Introduction
11.2.4 Merck Revenue in Central Nervous System Biomarker Detection Business (2020-2025)
11.2.5 Merck Recent Development
11.3 Takeda
11.3.1 Takeda Company Details
11.3.2 Takeda Business Overview
11.3.3 Takeda Central Nervous System Biomarker Detection Introduction
11.3.4 Takeda Revenue in Central Nervous System Biomarker Detection Business (2020-2025)
11.3.5 Takeda Recent Development
11.4 Pfizer
11.4.1 Pfizer Company Details
11.4.2 Pfizer Business Overview
11.4.3 Pfizer Central Nervous System Biomarker Detection Introduction
11.4.4 Pfizer Revenue in Central Nervous System Biomarker Detection Business (2020-2025)
11.4.5 Pfizer Recent Development
11.5 GSK
11.5.1 GSK Company Details
11.5.2 GSK Business Overview
11.5.3 GSK Central Nervous System Biomarker Detection Introduction
11.5.4 GSK Revenue in Central Nervous System Biomarker Detection Business (2020-2025)
11.5.5 GSK Recent Development
11.6 Novartis
11.6.1 Novartis Company Details
11.6.2 Novartis Business Overview
11.6.3 Novartis Central Nervous System Biomarker Detection Introduction
11.6.4 Novartis Revenue in Central Nervous System Biomarker Detection Business (2020-2025)
11.6.5 Novartis Recent Development
11.7 BristolMyers Squibb
11.7.1 BristolMyers Squibb Company Details
11.7.2 BristolMyers Squibb Business Overview
11.7.3 BristolMyers Squibb Central Nervous System Biomarker Detection Introduction
11.7.4 BristolMyers Squibb Revenue in Central Nervous System Biomarker Detection Business (2020-2025)
11.7.5 BristolMyers Squibb Recent Development
11.8 Biogen
11.8.1 Biogen Company Details
11.8.2 Biogen Business Overview
11.8.3 Biogen Central Nervous System Biomarker Detection Introduction
11.8.4 Biogen Revenue in Central Nervous System Biomarker Detection Business (2020-2025)
11.8.5 Biogen Recent Development
11.9 Celgene
11.9.1 Celgene Company Details
11.9.2 Celgene Business Overview
11.9.3 Celgene Central Nervous System Biomarker Detection Introduction
11.9.4 Celgene Revenue in Central Nervous System Biomarker Detection Business (2020-2025)
11.9.5 Celgene Recent Development
11.10 AbbVie
11.10.1 AbbVie Company Details
11.10.2 AbbVie Business Overview
11.10.3 AbbVie Central Nervous System Biomarker Detection Introduction
11.10.4 AbbVie Revenue in Central Nervous System Biomarker Detection Business (2020-2025)
11.10.5 AbbVie Recent Development
11.11 Johnson And Johnson
11.11.1 Johnson And Johnson Company Details
11.11.2 Johnson And Johnson Business Overview
11.11.3 Johnson And Johnson Central Nervous System Biomarker Detection Introduction
11.11.4 Johnson And Johnson Revenue in Central Nervous System Biomarker Detection Business (2020-2025)
11.11.5 Johnson And Johnson Recent Development
11.12 Amgen
11.12.1 Amgen Company Details
11.12.2 Amgen Business Overview
11.12.3 Amgen Central Nervous System Biomarker Detection Introduction
11.12.4 Amgen Revenue in Central Nervous System Biomarker Detection Business (2020-2025)
11.12.5 Amgen Recent Development
11.13 Eli Lilly
11.13.1 Eli Lilly Company Details
11.13.2 Eli Lilly Business Overview
11.13.3 Eli Lilly Central Nervous System Biomarker Detection Introduction
11.13.4 Eli Lilly Revenue in Central Nervous System Biomarker Detection Business (2020-2025)
11.13.5 Eli Lilly Recent Development
11.14 Sanofi
11.14.1 Sanofi Company Details
11.14.2 Sanofi Business Overview
11.14.3 Sanofi Central Nervous System Biomarker Detection Introduction
11.14.4 Sanofi Revenue in Central Nervous System Biomarker Detection Business (2020-2025)
11.14.5 Sanofi Recent Development
11.15 AstraZeneca
11.15.1 AstraZeneca Company Details
11.15.2 AstraZeneca Business Overview
11.15.3 AstraZeneca Central Nervous System Biomarker Detection Introduction
11.15.4 AstraZeneca Revenue in Central Nervous System Biomarker Detection Business (2020-2025)
11.15.5 AstraZeneca Recent Development
11.16 Quanterix
11.16.1 Quanterix Company Details
11.16.2 Quanterix Business Overview
11.16.3 Quanterix Central Nervous System Biomarker Detection Introduction
11.16.4 Quanterix Revenue in Central Nervous System Biomarker Detection Business (2020-2025)
11.16.5 Quanterix Recent Development
11.17 Biology Leader
11.17.1 Biology Leader Company Details
11.17.2 Biology Leader Business Overview
11.17.3 Biology Leader Central Nervous System Biomarker Detection Introduction
11.17.4 Biology Leader Revenue in Central Nervous System Biomarker Detection Business (2020-2025)
11.17.5 Biology Leader Recent Development
11.18 Dian Diagnostics
11.18.1 Dian Diagnostics Company Details
11.18.2 Dian Diagnostics Business Overview
11.18.3 Dian Diagnostics Central Nervous System Biomarker Detection Introduction
11.18.4 Dian Diagnostics Revenue in Central Nervous System Biomarker Detection Business (2020-2025)
11.18.5 Dian Diagnostics Recent Development
11.19 Roadak
11.19.1 Roadak Company Details
11.19.2 Roadak Business Overview
11.19.3 Roadak Central Nervous System Biomarker Detection Introduction
11.19.4 Roadak Revenue in Central Nervous System Biomarker Detection Business (2020-2025)
11.19.5 Roadak Recent Development
11.20 Delta Med Biotech
11.20.1 Delta Med Biotech Company Details
11.20.2 Delta Med Biotech Business Overview
11.20.3 Delta Med Biotech Central Nervous System Biomarker Detection Introduction
11.20.4 Delta Med Biotech Revenue in Central Nervous System Biomarker Detection Business (2020-2025)
11.20.5 Delta Med Biotech Recent Development
12 Analyst's Viewpoints/Conclusions
13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.1.1 Research Programs/Design
13.1.1.2 Market Size Estimation
13.1.1.3 Market Breakdown and Data Triangulation
13.1.2 Data Source
13.1.2.1 Secondary Sources
13.1.2.2 Primary Sources
13.2 Author Details
13.3 Disclaimer
List of Tables
Table 1. Global Central Nervous System Biomarker Detection Market Size Growth Rate by Type (US$ Million): 2020 VS 2024 VS 2031
Table 2. Key Players of Genetic Biomarkers Detection
Table 3. Key Players of Protein Biomarkers Detection
Table 4. Key Players of Metabolic Biomarkers Detection
Table 5. Key Players of Neuroimaging Biomarkers Detection
Table 6. Global Central Nervous System Biomarker Detection Market Size Growth by Application (US$ Million): 2020 VS 2024 VS 2031
Table 7. Global Central Nervous System Biomarker Detection Market Size by Region (US$ Million): 2020 VS 2024 VS 2031
Table 8. Global Central Nervous System Biomarker Detection Market Size by Region (2020-2025) & (US$ Million)
Table 9. Global Central Nervous System Biomarker Detection Market Share by Region (2020-2025)
Table 10. Global Central Nervous System Biomarker Detection Forecasted Market Size by Region (2026-2031) & (US$ Million)
Table 11. Global Central Nervous System Biomarker Detection Market Share by Region (2026-2031)
Table 12. Central Nervous System Biomarker Detection Market Trends
Table 13. Central Nervous System Biomarker Detection Market Drivers
Table 14. Central Nervous System Biomarker Detection Market Challenges
Table 15. Central Nervous System Biomarker Detection Market Restraints
Table 16. Global Central Nervous System Biomarker Detection Revenue by Players (2020-2025) & (US$ Million)
Table 17. Global Central Nervous System Biomarker Detection Market Share by Players (2020-2025)
Table 18. Global Top Central Nervous System Biomarker Detection Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Central Nervous System Biomarker Detection as of 2024)
Table 19. Ranking of Global Top Central Nervous System Biomarker Detection Companies by Revenue (US$ Million) in 2024
Table 20. Global 5 Largest Players Market Share by Central Nervous System Biomarker Detection Revenue (CR5 and HHI) & (2020-2025)
Table 21. Global Key Players of Central Nervous System Biomarker Detection, Headquarters and Area Served
Table 22. Global Key Players of Central Nervous System Biomarker Detection, Product and Application
Table 23. Global Key Players of Central Nervous System Biomarker Detection, Date of Enter into This Industry
Table 24. Mergers & Acquisitions, Expansion Plans
Table 25. Global Central Nervous System Biomarker Detection Market Size by Type (2020-2025) & (US$ Million)
Table 26. Global Central Nervous System Biomarker Detection Revenue Market Share by Type (2020-2025)
Table 27. Global Central Nervous System Biomarker Detection Forecasted Market Size by Type (2026-2031) & (US$ Million)
Table 28. Global Central Nervous System Biomarker Detection Revenue Market Share by Type (2026-2031)
Table 29. Global Central Nervous System Biomarker Detection Market Size by Application (2020-2025) & (US$ Million)
Table 30. Global Central Nervous System Biomarker Detection Revenue Market Share by Application (2020-2025)
Table 31. Global Central Nervous System Biomarker Detection Forecasted Market Size by Application (2026-2031) & (US$ Million)
Table 32. Global Central Nervous System Biomarker Detection Revenue Market Share by Application (2026-2031)
Table 33. North America Central Nervous System Biomarker Detection Market Size Growth Rate by Country (US$ Million): 2020 VS 2024 VS 2031
Table 34. North America Central Nervous System Biomarker Detection Market Size by Country (2020-2025) & (US$ Million)
Table 35. North America Central Nervous System Biomarker Detection Market Size by Country (2026-2031) & (US$ Million)
Table 36. Europe Central Nervous System Biomarker Detection Market Size Growth Rate by Country (US$ Million): 2020 VS 2024 VS 2031
Table 37. Europe Central Nervous System Biomarker Detection Market Size by Country (2020-2025) & (US$ Million)
Table 38. Europe Central Nervous System Biomarker Detection Market Size by Country (2026-2031) & (US$ Million)
Table 39. Asia-Pacific Central Nervous System Biomarker Detection Market Size Growth Rate by Region (US$ Million): 2020 VS 2024 VS 2031
Table 40. Asia-Pacific Central Nervous System Biomarker Detection Market Size by Region (2020-2025) & (US$ Million)
Table 41. Asia-Pacific Central Nervous System Biomarker Detection Market Size by Region (2026-2031) & (US$ Million)
Table 42. Latin America Central Nervous System Biomarker Detection Market Size Growth Rate by Country (US$ Million): 2020 VS 2024 VS 2031
Table 43. Latin America Central Nervous System Biomarker Detection Market Size by Country (2020-2025) & (US$ Million)
Table 44. Latin America Central Nervous System Biomarker Detection Market Size by Country (2026-2031) & (US$ Million)
Table 45. Middle East & Africa Central Nervous System Biomarker Detection Market Size Growth Rate by Country (US$ Million): 2020 VS 2024 VS 2031
Table 46. Middle East & Africa Central Nervous System Biomarker Detection Market Size by Country (2020-2025) & (US$ Million)
Table 47. Middle East & Africa Central Nervous System Biomarker Detection Market Size by Country (2026-2031) & (US$ Million)
Table 48. Roche Company Details
Table 49. Roche Business Overview
Table 50. Roche Central Nervous System Biomarker Detection Product
Table 51. Roche Revenue in Central Nervous System Biomarker Detection Business (2020-2025) & (US$ Million)
Table 52. Roche Recent Development
Table 53. Merck Company Details
Table 54. Merck Business Overview
Table 55. Merck Central Nervous System Biomarker Detection Product
Table 56. Merck Revenue in Central Nervous System Biomarker Detection Business (2020-2025) & (US$ Million)
Table 57. Merck Recent Development
Table 58. Takeda Company Details
Table 59. Takeda Business Overview
Table 60. Takeda Central Nervous System Biomarker Detection Product
Table 61. Takeda Revenue in Central Nervous System Biomarker Detection Business (2020-2025) & (US$ Million)
Table 62. Takeda Recent Development
Table 63. Pfizer Company Details
Table 64. Pfizer Business Overview
Table 65. Pfizer Central Nervous System Biomarker Detection Product
Table 66. Pfizer Revenue in Central Nervous System Biomarker Detection Business (2020-2025) & (US$ Million)
Table 67. Pfizer Recent Development
Table 68. GSK Company Details
Table 69. GSK Business Overview
Table 70. GSK Central Nervous System Biomarker Detection Product
Table 71. GSK Revenue in Central Nervous System Biomarker Detection Business (2020-2025) & (US$ Million)
Table 72. GSK Recent Development
Table 73. Novartis Company Details
Table 74. Novartis Business Overview
Table 75. Novartis Central Nervous System Biomarker Detection Product
Table 76. Novartis Revenue in Central Nervous System Biomarker Detection Business (2020-2025) & (US$ Million)
Table 77. Novartis Recent Development
Table 78. BristolMyers Squibb Company Details
Table 79. BristolMyers Squibb Business Overview
Table 80. BristolMyers Squibb Central Nervous System Biomarker Detection Product
Table 81. BristolMyers Squibb Revenue in Central Nervous System Biomarker Detection Business (2020-2025) & (US$ Million)
Table 82. BristolMyers Squibb Recent Development
Table 83. Biogen Company Details
Table 84. Biogen Business Overview
Table 85. Biogen Central Nervous System Biomarker Detection Product
Table 86. Biogen Revenue in Central Nervous System Biomarker Detection Business (2020-2025) & (US$ Million)
Table 87. Biogen Recent Development
Table 88. Celgene Company Details
Table 89. Celgene Business Overview
Table 90. Celgene Central Nervous System Biomarker Detection Product
Table 91. Celgene Revenue in Central Nervous System Biomarker Detection Business (2020-2025) & (US$ Million)
Table 92. Celgene Recent Development
Table 93. AbbVie Company Details
Table 94. AbbVie Business Overview
Table 95. AbbVie Central Nervous System Biomarker Detection Product
Table 96. AbbVie Revenue in Central Nervous System Biomarker Detection Business (2020-2025) & (US$ Million)
Table 97. AbbVie Recent Development
Table 98. Johnson And Johnson Company Details
Table 99. Johnson And Johnson Business Overview
Table 100. Johnson And Johnson Central Nervous System Biomarker Detection Product
Table 101. Johnson And Johnson Revenue in Central Nervous System Biomarker Detection Business (2020-2025) & (US$ Million)
Table 102. Johnson And Johnson Recent Development
Table 103. Amgen Company Details
Table 104. Amgen Business Overview
Table 105. Amgen Central Nervous System Biomarker Detection Product
Table 106. Amgen Revenue in Central Nervous System Biomarker Detection Business (2020-2025) & (US$ Million)
Table 107. Amgen Recent Development
Table 108. Eli Lilly Company Details
Table 109. Eli Lilly Business Overview
Table 110. Eli Lilly Central Nervous System Biomarker Detection Product
Table 111. Eli Lilly Revenue in Central Nervous System Biomarker Detection Business (2020-2025) & (US$ Million)
Table 112. Eli Lilly Recent Development
Table 113. Sanofi Company Details
Table 114. Sanofi Business Overview
Table 115. Sanofi Central Nervous System Biomarker Detection Product
Table 116. Sanofi Revenue in Central Nervous System Biomarker Detection Business (2020-2025) & (US$ Million)
Table 117. Sanofi Recent Development
Table 118. AstraZeneca Company Details
Table 119. AstraZeneca Business Overview
Table 120. AstraZeneca Central Nervous System Biomarker Detection Product
Table 121. AstraZeneca Revenue in Central Nervous System Biomarker Detection Business (2020-2025) & (US$ Million)
Table 122. AstraZeneca Recent Development
Table 123. Quanterix Company Details
Table 124. Quanterix Business Overview
Table 125. Quanterix Central Nervous System Biomarker Detection Product
Table 126. Quanterix Revenue in Central Nervous System Biomarker Detection Business (2020-2025) & (US$ Million)
Table 127. Quanterix Recent Development
Table 128. Biology Leader Company Details
Table 129. Biology Leader Business Overview
Table 130. Biology Leader Central Nervous System Biomarker Detection Product
Table 131. Biology Leader Revenue in Central Nervous System Biomarker Detection Business (2020-2025) & (US$ Million)
Table 132. Biology Leader Recent Development
Table 133. Dian Diagnostics Company Details
Table 134. Dian Diagnostics Business Overview
Table 135. Dian Diagnostics Central Nervous System Biomarker Detection Product
Table 136. Dian Diagnostics Revenue in Central Nervous System Biomarker Detection Business (2020-2025) & (US$ Million)
Table 137. Dian Diagnostics Recent Development
Table 138. Roadak Company Details
Table 139. Roadak Business Overview
Table 140. Roadak Central Nervous System Biomarker Detection Product
Table 141. Roadak Revenue in Central Nervous System Biomarker Detection Business (2020-2025) & (US$ Million)
Table 142. Roadak Recent Development
Table 143. Delta Med Biotech Company Details
Table 144. Delta Med Biotech Business Overview
Table 145. Delta Med Biotech Central Nervous System Biomarker Detection Product
Table 146. Delta Med Biotech Revenue in Central Nervous System Biomarker Detection Business (2020-2025) & (US$ Million)
Table 147. Delta Med Biotech Recent Development
Table 148. Research Programs/Design for This Report
Table 149. Key Data Information from Secondary Sources
Table 150. Key Data Information from Primary Sources
Table 151. Authors List of This Report


List of Figures
Figure 1. Central Nervous System Biomarker Detection Picture
Figure 2. Global Central Nervous System Biomarker Detection Market Size Comparison by Type (2020-2031) & (US$ Million)
Figure 3. Global Central Nervous System Biomarker Detection Market Share by Type: 2024 VS 2031
Figure 4. Genetic Biomarkers Detection Features
Figure 5. Protein Biomarkers Detection Features
Figure 6. Metabolic Biomarkers Detection Features
Figure 7. Neuroimaging Biomarkers Detection Features
Figure 8. Global Central Nervous System Biomarker Detection Market Size by Application (2020-2031) & (US$ Million)
Figure 9. Global Central Nervous System Biomarker Detection Market Share by Application: 2024 VS 2031
Figure 10. Disease Diagnosis And Classification Case Studies
Figure 11. Surveillance Case Studies
Figure 12. Prognosis Case Studies
Figure 13. Drug Development Case Studies
Figure 14. Others Case Studies
Figure 15. Central Nervous System Biomarker Detection Report Years Considered
Figure 16. Global Central Nervous System Biomarker Detection Market Size (US$ Million), Year-over-Year: 2020-2031
Figure 17. Global Central Nervous System Biomarker Detection Market Size, (US$ Million), 2020 VS 2024 VS 2031
Figure 18. Global Central Nervous System Biomarker Detection Market Share by Region: 2024 VS 2031
Figure 19. Global Central Nervous System Biomarker Detection Market Share by Players in 2024
Figure 20. Global Central Nervous System Biomarker Detection Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
Figure 21. The Top 10 and 5 Players Market Share by Central Nervous System Biomarker Detection Revenue in 2024
Figure 22. North America Central Nervous System Biomarker Detection Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 23. North America Central Nervous System Biomarker Detection Market Share by Country (2020-2031)
Figure 24. United States Central Nervous System Biomarker Detection Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 25. Canada Central Nervous System Biomarker Detection Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 26. Europe Central Nervous System Biomarker Detection Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 27. Europe Central Nervous System Biomarker Detection Market Share by Country (2020-2031)
Figure 28. Germany Central Nervous System Biomarker Detection Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 29. France Central Nervous System Biomarker Detection Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 30. U.K. Central Nervous System Biomarker Detection Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 31. Italy Central Nervous System Biomarker Detection Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 32. Russia Central Nervous System Biomarker Detection Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 33. Nordic Countries Central Nervous System Biomarker Detection Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 34. Asia-Pacific Central Nervous System Biomarker Detection Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 35. Asia-Pacific Central Nervous System Biomarker Detection Market Share by Region (2020-2031)
Figure 36. China Central Nervous System Biomarker Detection Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 37. Japan Central Nervous System Biomarker Detection Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 38. South Korea Central Nervous System Biomarker Detection Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 39. Southeast Asia Central Nervous System Biomarker Detection Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 40. India Central Nervous System Biomarker Detection Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 41. Australia Central Nervous System Biomarker Detection Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 42. Latin America Central Nervous System Biomarker Detection Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 43. Latin America Central Nervous System Biomarker Detection Market Share by Country (2020-2031)
Figure 44. Mexico Central Nervous System Biomarker Detection Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 45. Brazil Central Nervous System Biomarker Detection Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 46. Middle East & Africa Central Nervous System Biomarker Detection Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 47. Middle East & Africa Central Nervous System Biomarker Detection Market Share by Country (2020-2031)
Figure 48. Turkey Central Nervous System Biomarker Detection Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 49. Saudi Arabia Central Nervous System Biomarker Detection Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 50. UAE Central Nervous System Biomarker Detection Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 51. Roche Revenue Growth Rate in Central Nervous System Biomarker Detection Business (2020-2025)
Figure 52. Merck Revenue Growth Rate in Central Nervous System Biomarker Detection Business (2020-2025)
Figure 53. Takeda Revenue Growth Rate in Central Nervous System Biomarker Detection Business (2020-2025)
Figure 54. Pfizer Revenue Growth Rate in Central Nervous System Biomarker Detection Business (2020-2025)
Figure 55. GSK Revenue Growth Rate in Central Nervous System Biomarker Detection Business (2020-2025)
Figure 56. Novartis Revenue Growth Rate in Central Nervous System Biomarker Detection Business (2020-2025)
Figure 57. BristolMyers Squibb Revenue Growth Rate in Central Nervous System Biomarker Detection Business (2020-2025)
Figure 58. Biogen Revenue Growth Rate in Central Nervous System Biomarker Detection Business (2020-2025)
Figure 59. Celgene Revenue Growth Rate in Central Nervous System Biomarker Detection Business (2020-2025)
Figure 60. AbbVie Revenue Growth Rate in Central Nervous System Biomarker Detection Business (2020-2025)
Figure 61. Johnson And Johnson Revenue Growth Rate in Central Nervous System Biomarker Detection Business (2020-2025)
Figure 62. Amgen Revenue Growth Rate in Central Nervous System Biomarker Detection Business (2020-2025)
Figure 63. Eli Lilly Revenue Growth Rate in Central Nervous System Biomarker Detection Business (2020-2025)
Figure 64. Sanofi Revenue Growth Rate in Central Nervous System Biomarker Detection Business (2020-2025)
Figure 65. AstraZeneca Revenue Growth Rate in Central Nervous System Biomarker Detection Business (2020-2025)
Figure 66. Quanterix Revenue Growth Rate in Central Nervous System Biomarker Detection Business (2020-2025)
Figure 67. Biology Leader Revenue Growth Rate in Central Nervous System Biomarker Detection Business (2020-2025)
Figure 68. Dian Diagnostics Revenue Growth Rate in Central Nervous System Biomarker Detection Business (2020-2025)
Figure 69. Roadak Revenue Growth Rate in Central Nervous System Biomarker Detection Business (2020-2025)
Figure 70. Delta Med Biotech Revenue Growth Rate in Central Nervous System Biomarker Detection Business (2020-2025)
Figure 71. Bottom-up and Top-down Approaches for This Report
Figure 72. Data Triangulation
Figure 73. Key Executives Interviewed
Choose Your Edition
Add to cart

Our team would be happy to assist you with your queries.

Contact us

About us

Accurate data, The latest market trends, And deeper research directions.

Our sole purpose is to provide a basis for leaders in all walks of life to make more appropriate decisions, to help companies solve existing problems and achieve business goals

Latest reports

Useful links

Our Contacts

Room 2306, T6 Fuxing World Financial Center, Kaifu District, Changsha, Hunan, China

(+86) 159 1069 5232

sales@hengceresearch.com
hengceresearch.com

Allow cookies